Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1951]
News [3931]
Articles [104]
Editorials [5]
Conferences [164]
elearning [26]
ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years
ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years
Dual PET imaging detects tumor progression and heart inflammation during cancer treatment
Dual PET imaging detects tumor progression and heart inflammation during cancer treatment
ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior
ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible...
ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer
ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer
ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and reduce side effects for advanced head and neck cancer
ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and...
ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell lymphomas
ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell...
ASCO 2026: Addition of immunotherapy continues to show survival benefit in prolonged follow-up in primary advanced stage or recurrent endometrial cancer
ASCO 2026: Addition of immunotherapy continues to show survival benefit in prolonged follow-up in primary advanced...
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive bladder cancer
FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive bladder cancer
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare haematologic malignancy
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare haematologic...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation